Inhibikase Therapeutics (IKT) Liabilities and Shareholders Equity (2020 - 2025)
Historic Liabilities and Shareholders Equity for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $79.6 million.
- Inhibikase Therapeutics' Liabilities and Shareholders Equity rose 171852.44% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $361.3 million, marking a year-over-year increase of 83177.84%. This contributed to the annual value of $98.6 million for FY2024, which is 57968.74% up from last year.
- As of Q3 2025, Inhibikase Therapeutics' Liabilities and Shareholders Equity stood at $79.6 million, which was up 171852.44% from $88.9 million recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Liabilities and Shareholders Equity peaked at $98.6 million during Q4 2024, and registered a low of $4.4 million during Q3 2024.
- Moreover, its 5-year median value for Liabilities and Shareholders Equity was $28.6 million (2022), whereas its average is $39.1 million.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 7552.18% in 2024, then soared by 171852.44% in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $42.5 million in 2021, then crashed by 41.28% to $24.9 million in 2022, then tumbled by 41.83% to $14.5 million in 2023, then surged by 579.69% to $98.6 million in 2024, then fell by 19.28% to $79.6 million in 2025.
- Its last three reported values are $79.6 million in Q3 2025, $88.9 million for Q2 2025, and $94.3 million during Q1 2025.